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Background: There are controversies regarding the accuracy of the tuberculin skin test (TST) and methods based
on the production of interferon gamma by sensitized T cells for the diagnosis of latent tuberculosis infection (LTBI)
in pediatrics and immunosuppressed patients. Our objectives are to study TST and ELISPOT/T. SPOT.TB in the
diagnosis of LTBI in children and adolescents with JIA undergoing methotrexate, the correlation between both and
the sensitivity and specificity of T. SPOT.TB.
Methods: This is an observational prospective longitudinal study in which children and adolescents with JIA
undergoing methotrexate therapy were assessed for clinical and epidemiological data for LTBI, in addition to
performing TST and T. SPOT.TB at baseline and after 3 and 12 months.
Results: There were 24 patients. The prevalence of LTBI at inclusion was 20.8%, the incidence after initiation of
immunosuppressions 26.3% and the prevalence at the end of the study 41.6%. Epidemiological history positive for
TB showed a relative risk of 2.0 for the development of LTBI. Only 2 patients had positive T. SPOT.TB but only in one
it was useful for detecting early LTBI. T. SPOT.TB presented a sensitivity of 10%, specificity of 92.8%, and low
correlation with TST. No patient developed TB disease at a mean follow-up of 47 months.
Conclusions: We found a high prevalence of ILTB that doubled with immunosuppression and that epidemiological
history was an important relative risk. T. SPOT.TB showed low sensitivity and high specificity, and no superiority over
TST. There was low agreement and little influence of immunosuppression on the results of both tests.Background
It is estimated that one third of the world’s population is
infected with Mycobacterium tuberculosis (M. tb) and
15-20% of new cases occur in children and adolescents
[1]. In most cases, the infection remains latent. Never-
theless, latent tuberculosis infection (LTBI) can persist
with risk of progression to disease in about 10% in
the general population and 15-43% in the pediatric
age group and is an important cause of morbidity and
mortality, especially in immunossupressed patients [2,3].
LTBI is the clinical syndrome caused by exposure to M.
tb followed by infection, evidenced by the presence of
positive tuberculin skin test (TST) in the absence of* Correspondence: flaviosztajnbok@hotmail.com
1Pediatric Rheumatology Division, Universidade Federal do Rio de Janeiro,
Rua Bruno Lobo 50, Cidade Universitária, 21941-912 Rio de Janeiro, Brasil
Full list of author information is available at the end of the article
© 2014 Sztajnbok et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.clinical and radiological signs and symptoms of disease
activity [4,5]. To confirm the diagnosis of LTBI, epidemio-
logical data, personal and familiar history, physical exam-
ination and laboratorial results should be considered.
There is no confirmatory test for the diagnosis of LTBI
and TST is still considered the gold standard, despite
some limitations. In immunosuppressed patients, TST
may present lower sensitivity and false negative results
may occur, making LTBI diagnosis even more difficult [6].
Diagnostic tests in vitro using whole blood to assess
the production of interferon-gamma (IFN -γ) by previ-
ously sensitized lymphocytes were developed in order to
assist the diagnosis of tuberculosis (TB). These tests,
known as IGRA (interferon-gamma release assay), are
commercially available and the most frequently used are
the QuantiFERON-TB In-Tube® (enzyme linked immu-
nosorbent assay) and T. SPOT.TB ®/ELISPOT (enzymeral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and are not performed directly on the patient, reducing
the possibility of occurring adverse effects, booster effect
when repeated and abscence of the patient at the time of
reading. However, they are expensive and require spe-
cialized laboratories.
In general, different studies have shown 60-80% agree-
ment comparing TST and IGRAs in adults [7]. Some au-
thors [8,9] suggested that T. SPOT.TB presents better
sensitivity and specificity than TST in children. But few
studies have been conducted in immunosuppressed pa-
tients. The T. SPOT.TB assay has shown superiority
compared to TST sensitivity and specificity for diagnosis
of active TB in immunosuppressed patients [10]. How-
ever, most studies have been conducted in countries
with low TB incidence and in adult population [7,8].
Studies to determine the sensitivity and specificity of
IGRAs in immunocompromised children, especially from
endemic areas, are still lacking.
Juvenile idiopathic arthritis (JIA) is the most common
cause of chronic arthritis in pediatric age and its patho-
genesis is associated with changes in the immune system
[11]. This may explain the great predisposition of JIA pa-
tients to infections, beyond the fact that they frequently
use immunosuppressive drugs as treatment [12]. In
adults, rheumatoid arthritis itself, regardless the type of
treatment, may be associated with increased incidence of
TB, and it raises with the use of immunosuppressive
drugs, especially the modern biologic agents, but no data
is known for children [13].
BCG is the only available vaccine for TB and provides
protection against meningitis and disseminated forms.
The World Health Organization (WHO) recommends
that children from high-burden countries should be
vaccinated at birth, a practice common in most of these
countries. In low-burden countries this practice is re-
stricted to children from high-risk groups for TB [4].
Early diagnosis and treatment of LTBI are challenges to
be achieved in order to control TB worldwide. There is a
need for more studies on the accuracy of diagnostic me-
thods for TB in children and immunosuppressed patients,
especially in high-burden countries. This study aimed to
evaluate the frequency of LTBI and the sensitivity and spe-
cificity of the T. SPOT.TB compared to TST in the diag-
nosis of LTBI in patients with JIA before and after the use
of methotrexate (MTX), as it is the first-choice second-
line agent most frequently used in JIA [14], in a high-
burden country where most children receive BCG at birth.
Methods
This was an observational prospective longitudinal one-
year duration study approved by the local IRB. Children
and adolescents with JIA (Edmonton Revision, 2001
[15]) and indication to use MTX without previous orcurrent diagnosis of TB disease and no prior use of im-
munosuppressive drugs in the previous six months, were
consecutively included from March 2008 to September
2011. All patients received MTX at a dosage of 10–
15 mg/m2/week as the first second line drug after non-
steroidal antiinflammatory drug (NSAID) failure, as the
usual practice in our unit. If during the one-year follow-
up corticosteroid or a biologic agent was necessary, the
patient could continue in the study. However patients
with indication to start a biologic agent were not in-
cluded as these drugs are known to increase TB inci-
dence [13] and they were already using MTX.
All patients answered a questionnaire to assess epi-
demiological data regarding TB at the first visit (T0).
The intention was to evaluate contact with suspected
cases of TB, presence of signs and symptoms suggestive
of TB in patients and their families and previous treat-
ment of LTBI or active disease. The questionnaire in-
cluded previous BCG vaccination and the presence of
the charactheristic skin scar (later confirmed by a phy-
sician), results of previous TST eventually performed, pre-
vious history, treatment or signs and symptoms of TB
(patient and the family: unexplainned prolonged fever,
prolonged cough, pulmonary or pleural disorders), socio-
economic conditions of the residence and neighborhood
and contact with persons with TB.
At T0 chest radiography, TST, and basic laboratory
tests such as complete blood count, acute phase reac-
tants, assessment of renal and hepatic function, urinaly-
sis, HIV and the T. SPOT.TB test were ordered. TST
and T. SPOT.TB were also performed in the 3rd (T3)
and 12th (T12) months. Chest radiography was repeated
if either of the TB related tests became positive.
TST consisted of intradermal injection of 0.1 ml of
purified protein derivative (PPD RT 23 2 IU) of M. tb,
according to local practice. Patients were considered to
have a positive TST if an induration ≥ 5 mm diameter
was present 48–72 hours after inoculation [4]. The T.
SPOT.TB/ELISPOT test was performed according to the
manufacturer’s recommendations. The test included sec-
tions with negative control (C-: no mitogens or antigens),
sections with positive control (C +: phytohemagglutinin)
and sections to test two antigens (ESAT-6 and CFP-10).
Spot-forming units (SFUs) were counted with the aid of a
magnifying glass. Interpretation of the results was made as
follows: when the negative control contained ≤ 5 SFUs,
this value was subtracted from the number of SFUs found
in the section containing the antigens ESAT-6 and CFP-
10, and so: positive test ≥ 6 SFUs for either antigen; nega-
tive test ≤ 6 SFUs for both antigens and ≥ 20 SFUs in the
positive control section; indeterminate test ≤ 6 SFUs for
both antigens and ≤ 20 SFUs in the positive control sec-
tion. In case the negative control section presented with ≥
6 SFUs, the test was considered positive if the number of
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found in the negative control section. Samples of children
with bacteriological TB were used as external control. The
techinican performing the tests had no knowledge of clin-
ical or laboratory data of the patients.
Descriptive statistics were used to obtain absolute fre-
quencies and percentages for qualitative data, as well as
means, medians, and standard deviations for quantitative
data. The relationship between epidemiological history
and the presence of LTBI was evaluated by chi-square
test (significant if p value was less than 0.05). The sen-
sitivity, specificity, positive predictive value (PPV) and
negative predictive value (NPV) were calculated from
2×2 contingency tables, using the free program “Openepi”.
The kappa statistic was adopted to quantify the agreement
between the results of TST and T. SPOT.TB using “Statis-
tical Package for Social Sciences” (SPSS) version 16.0. The
agreement was considered poor for kappa values less than
0.41, moderate between 0.41 and 0.60, substantial be-
tween 0.61 and 0.80, and excellent when kappa was
more than 0.81.
Results
The study included 29 patients with JIA but because of
non-adherence to the protocol before visit T3, five pa-
tients were discontinued and, thus, 24 patients remained
in the study. Epidemiological and clinical data of the
patients at baseline are shown in Table 1. There were 17
female patients (70.8%). Ten patients (41.7%) were polyar-
ticular rheumatoid-factor negative, nine (37.5%) oligoarti-




Patients’ age at JIA diagnosis (range; mean; median)
Timeframe between JIA diagnosis and inclusion in the study (range; mea
Disease duration: timeframe between JIA onset and inclusion in the stu
(range; mean; median)
Patients’ age at inclusion (range; mean; median)
Epidemiological history of contact with TB at inclusion (T0)
Time is referred in months.for MTX onset was 30 months after diagnosis and 35
months after disease onset. All children received BCG
vaccine at birth as a current practice in Brazil. Twenty
patients were using NSAIDs and four were out of medi-
cations at the time of MTX onset. During the one-year
follow-up, no patient needed to use corticosteroid or a
biologic agent.
At T0, eight patients had positive epidemiological
history for TB and five of them developed LTBI. Of 16
patients without a positive epidemiological history, five
developed LTBI. The relative risk was 2 for patients with
epidemiological history for TB compared to those with-
out. None of the patients with positive results for T.
SPOT.TB had a positive epidemiological history for TB.
All 24 patients in the study had normal chest radiog-
raphy at T0 and there were no reports of new positive
epidemiological history of TB at T3 and T12.
At T0, before MTX onset, five patients already had a
positive TST. At T12, no patient had developed TB dis-
ease and 10 had developed LTBI. Thus, LTBI was diag-
nosed in 5/24 (20.8%) patients at T0 and 5/19 (26.3%)
patients after immunosuppression onset, what means
10/24 (41.6%) patients from T0 to T12. All patients with
positive TST were treated for LTBI with isoniazid for six
months, and there was no occurrence of toxicity in any
of them. All those with conversion of TST had a new
chest X-ray, which was normal in all cases. No patient
had a TST in the previous 2years before T0.
The agreement between TST and T. SPOT.TB could
not be assessed at T0 due to the fact that all results were




Polyarticular rheumatoid factor negative 10 41,7
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a negative test. Thus, there was a poor correlation be-
tween the two tools (κ = 0.11 and 0.16, respectively).
To evaluate the sensitivity and specificity of the T.
SPOT.TB, we considered TST value ≥ 5 mm as the gold
standard. At T3 the sensitivity of T. SPOT.TB was 20%
(CI 95% = 3.6 to 62.4) and the specificity 89.4% (CI 95% =
68.6 to 97), and at T12 12.5% (CI 95% = 2.2 to 47) and
100% (CI 95% = 80.6 to 100), respectively. Taking into ac-
count that 10 patients had LTBI, the final sensitivity of the
T. SPOT.TB was 10% (CI 95% = 1.7 to 40.4) and specificity
was 92.8% (CI 95% = 68.5 to 98.7). In this scenario, the
PPV of the T. SPOT.TB was 50% (CI 95% = 9.4 to 90.5)
and the NPV was 59% (CI 95% = 38.7 to 76.7). A ROC
curve for T. SPOT.TB showed an area under the curve of
0.51 (p value 0.81).
No other immunosuppressive therapy was initiated
and no MTX discontinued during the one-year study
follow-up. In the last appointment in March 2013, after
a mean follow-up of 3 years and 11 months, no patient
in the study had developed active TB. Table 2 shows
clinical and epidemiological data besides TST and
T. SPOT.TB results for each subject in the study.
Discussion
To our knowledge, this study was the first to assess the
performance of TST and T. SPOT.TB in pediatric pa-
tients with a rheumatic disease in a high-burden coun-
try. Brazil presents a high incidence of TB, around 38
cases per 100.000 inhabitants in 2011 [16].
In our study, the epidemiological history for TB dou-
bled the relative risk for the development of LTBI com-
pared to patients with negative epidemiological history.
In a systematic review in which 40% of the studies were
conducted in countries where TB was endemic, it was
found an association between positive epidemiological
history and responses in TST and IGRAs [17]. The au-
thors suggested that an important marker to be consid-
ered for the diagnosis of LTBI would be the degree of
exposure of the patient, i.e. location, number of hours of
exposure to a person with TB and bacillary load. Unfor-
tunately, in our study, such an assessment was virtually
impossible because the lack of information provided by
the assisted population. Thus, our study considered only
yes/no responses concerning exposure.
The conversion of TST usually occurs about two to
12 weeks after infection and the T. SPOT.TB between
four and 22 weeks [18]. In one patient (#13), T. SPOT.
TB presented a positive result prior to TST conversion
and, at least in this case, T. SPOT.TB was sensitive
enough to identify LTBI in advance. In the other patient
(#12), T. SPOT.TB became negative at T12 and TST
remained negative. One explanation for this latter pa-
tient could be the occurrence of a booster effect becauseIGRA in T3 was performed sometime after TST in this
patient. This is a rare but possible event [19,20].
No patient developed active TB during the one-year
follow-up of the study. All patients had a prolonged
follow-up after this initial proposed study time (one
year), with a mean time of 3 years and 11 months, and
although in this phase there were patients who started
biologic agents, none of them developed active TB. We
believe that this fact was possibly due to the early treat-
ment of LTBI [21].
We did not find national or international data to com-
pare our high rates of LTBI as most of the data available
refers to active TB. The most comparable to ours, as
conditions of patients at risk for acquiring LTBI, were
reported rates of LTBI in 61.5% of subjects in a prison
hospital, 40% of shelter residents, and 20% of injection
drug users [22]. Besides the high incidence of TB in
Brazil, additional factors that could explain the high
rates of LTBI in our study are the immunosuppression
associated with JIA itself, patients’ frequent exposure to
health services and possible TB, and the use of MTX.
Our study showed poor correlation between the re-
sults of TST and T. SPOT.TB. The few available studies
showed that such an agreement appears to be low in
countries where TB is endemic, unlikely in countries
with low incidence, and this could be explained by the
high sensitivity inherent to TST revealing false negative
IGRAs [5,19,23,24]. It should be noted that patients re-
ceived BCG at birth, many years before study partici-
pation, so BCG very probably did not influence TST
results. It is known that TST positivity associated to
BCG in the neonatal age decreases rapidly in a few years
[25]. TST positivity could not be explained by a booster
effect, as no patient had TST performed in the two years
prior to the study onset.
Immunosuppression may affect the sensitivity of both
TST and IGRAs [23,26]. Although in immunosup-
pressed adults IGRAs showed higher sensitivity than
TST [21,27,28], some authors found lower values for
both TST and IGRAs in patients with rheumatoid arthritis
using immunosuppressants compared to those not using
immunosuppressants [23]. For the TST cut-off value of
5 mm as used in Brazil [4], IGRAs showed high specificity
and low sensitivity. At this cut-off, TST performed better
than T. SPOT.TB. In our study, it was difficult to evaluate
the role of immunosuppression on the results of T. SPOT.
TB, since all were negative at T0, before MTX onset. Be-
tween T3 and T12 sensitivity, which was already low,
slightly decreased. It was not possible to explain why four
patients showed conversion of TST during the study and
the T. SPOT.TB remained negative. Although TST and T.
SPOT.TB evaluate different responses, it would be ex-
pected that immunosuppression could influence TST
more often than IGRAs, since the former depends on the
Table 2 Epidemiological and clinical data besides TST and T. SPOT.TB/ELISPOT results from the 24 cases






T0 T3 T12 Follow up
(months)
LTBI
1 P 72 16 88 TST 0 TST0 TST 0 57
M Elispot - Elispot - Elispot -
2* O 20 90 110 TST 0 TST 4 TST 10 58 yes
F Elispot - Elispot - Elispot -
3 P 152 2 154 TST 7 TST 0 TST 0 59 yes
F Elispot - Elispot - Elispot -
4 O 192 24 216 TST 0 TST 0 TST 0 59
F Elispot - Elispot - Elispot -
5* P 130 6 136 TST 5 TST 19 TST 12 55 yes
F Elispot - Elispot - Elispot -
6* O 88 1 89 TST 0 TST 0 TST 0 56
M Elispot - Elispot - Elispot -
7* S 102 2 104 TST 0 TST 10 TST 10 56 Yes
F Elispot - Elispot - Elispot -
8 O 84 106 190 TST 14 TST 10 TST 15 56 Yes
F Elispot - Elispot - Elispot -
9 O 108 99 207 TST 13 TST 15 TST 13 56 Yes
M Elispot - Elispot - Elispot -
10 O 86 30 116 TST 0 TST 0 TST 0 55
F Elispot - Elispot - Elispot -
11 S 113 1 114 TST 0 TST 0 TST 0 53
F Elispot - Elispot - Elispot -
12 S 24 46 70 TST 0 TST 0 TST 0 37
F Elispot - Elispot + Elispot -
13 P 139 4 143 TST 0 TST 0 TST 10 52 Yes
M Elispot - Elispot + Elispot +
14* P 111 12 123 TST 3 TST 3 TST 0 51
M Elispot - Elispot - Elispot -
15* O 85 108 193 TST 0 TST 0 TST 0 50
F Elispot - Elispot - Elispot -
16 S 54 48 102 TST 1 TST 0 TST 0 29
F Elispot - Elispot - Elispot -
17 O 60 90 150 TST 0 TST 0 TST 0 29
F Elispot - Elispot - Elispot -
18 S 66 1 67 TST 0 TST 0 TST 0 28
F Elispot - Elispot - Elispot -
19* P 156 32 188 TST 0 TST 0 TST 23 25 Yes
M Elispot - Elispot - Elispot -
20 P 160 1 161 TST 0 TST 0 TST 0 19
F Elispot - Elispot - Elispot -
21 P 61 1 62 TST 0 TST 0 TST 0 18
F Elispot - Elispot - Elispot -
22 O 35 1 36 TST 0 TST 10 TST 10 60 Yes
F Elispot - Elispot - Elispot -
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Table 2 Epidemiological and clinical data besides TST and T. SPOT.TB/ELISPOT results from the 24 cases (Continued)
23 P 96 2 98 TST 0 TST 0 TST 0 57
F Elispot - Elispot - Elispot -
24* P 216 1 217 TST 5 TST 4 TST 2 57 Yes
M Elispot - Elispot - Elispot -
Legend:
• JIA = JIA subtypes: O = oligoarticular JIA; P= polyarticular JIA; S= systemic JIA.
• (*) = epidemiological hystory positive for TB.
• TST: in millimeters.
• T.SPOT.TB/ELISPOT : (-) = negative; (+) = positive.
• T0: study onset; T3: 3rd month; T12: 12th month.
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Therefore, in our patients, immunosuppression from
MTX did not influence the results of T. SPOT.TB.
T. SPOT.TB in children from endemic areas has
shown lower sensitivity and higher specificity than TST
[30,31]. It had been shown that IGRAs presented bet-
ter accuracy than the TST for the diagnosis of TB in
immunocompromised children [17], but a recent study
showed that IGRAs in children and immunosuppressed
patients might present false-negative results in endemic
areas for TB [32]. Throughout our study, T. SPOT.TB
showed low sensitivity but high specificity. If a positive
T. SPOT.TB was used for the diagnosis and indication
for treatment of LTBI in our patients, only two of them
would have been diagnosed as LTBI and treated. This
could mean that, in a high-burden setting, patients might
be untreated. On the other hand, it has been proposed
that in low-burden settings replacing TST with IGRA for
determining LTBI could allow a reduction in the number
of patients receiving treatment [28].
A study with epidemiological characteristics similar to
ours compared the use of TST and T. SPOT.TB in the
diagnosis of LTBI in adult patients with rheumatoid
arthritis and indication for use of biological agents. The
specificity of the T. SPOT.TB ranged from 87% to 90%
and NPV from 94.4% to 100%, with similar sensitivity to
TST. Authors suggested that the low sensitivity of T.
SPOT.TB in endemic areas for TB could be explained by
the fact that the antigens in the T. SPOT.TB plate, al-
though specific for M. tb, represented a small portion of
numerous antigens, and more reliable results could be
achieved by adding new antigens to the method [33]. In
Gambia, a TB- endemic region, T. SPOT.TB and TST
had similar results in the diagnosis of LTBI in children
vaccinated with BCG at an early age. TST and IGRA in
conjunction increased sensitivity in only 10% [20].
Our study had limitations, but many of them bring us
to real-life conditions, especially in developing countries.
The low prevalence of JIA might explain the difficulty to
include patients [11] and, unfortunatelly, there was no
possibility to test the real state of immunosuppression in
patients by assessing CD4 and CD8 counts.Recently, WHO recommended that IGRAs should not
be used in low- and middle-income countries (generally
those with higher TB burden), as there are insufficient
data and evidence on the performance of IGRAs in these
populations [4]. IGRAs have similar performance to TST
but are more expensive and complex to perform [4,34]
and, therefore, TST should be preferred in these settings.
However, data from pediatric population and immuno-
suppressed individuals who could benefit from IGRAs
are limited and more studies with large sample sizes
are desirable.
Conclusion
In conclusion, we found a high frequency of LTBI among
patients with JIA, which doubled after one year of MTX
therapy. There was a low agreement between TST and T.
SPOT.TB, low sensitivity and high specificity for the T.
SPOT.TB, and small influence of immunosuppression
related to MTX use on the performance of both. Even
with MTX, no cases treated for LTBI developed active TB.
There was no superiority of T. SPOT.TB compared to
TST for the diagnosis and monitoring of LTBI in childen
with JIA using MTX.
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